ASH 2018 | iFCG for IGHV-mutated CLL in the frontline
Please rate this video
Thanks for your feedback, this will help us improve our content for you!
Susan O’Brien, MD, of the University of California, Irvine, CA, provides an overview of the Phase II trial (NCT02629809) assessing the combination of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) as a frontline therapy for patients with IGHV-mutated chronic lymphocytic leukemia (CLL) vs. the current standard of care, FCR chemoimmunotherapy. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien discusses the increased efficacy of this combination, allowing short-duration chemotherapy and minimizing potential toxicities, and also reveals the higher rates of undetectable MRD with the iFCG regimen.
Warning: count(): Parameter must be an array or an object that implements Countable in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 241
Get great new content delivered to your inboxSign up
Warning: Invalid argument supplied for foreach() in /home/vjhemonc/public_html/wp-content/themes/vj/single.php on line 436